RGNX regenxbio.com Market Value

REGENXBIO Inc. (RGNX) is currently facing rising operating expenses due to costly research, which is temporarily limiting profitability. This chart reflects a market capitalization of 0.51. The business relies on the development of gene therapies and viral platforms, generating revenue from licensing royalties. Margin stability is supported by an extensive network of laboratories that minimize risks when transporting biomaterials under extreme cold conditions.

RGNX (regenxbio.com) Market Capitalization history from 07/04/2022 to 11/15/2026

REGENXBIO Inc. - analytical breakdowns and key metrics (RGNX)

- current price and projected stock value:

Stock Price REGENXBIO Inc|RGNX - Analyst Target Range

- market capitalization data:

Market Value Regenxbio|RGNX - Business Value

- book value of equity indicators:

Accounting Value per Share REGENXBIO|RGNX - Accounting Capitalization|Market Capitalization to Book Value Ratio regenxbio.com|RGNX - Total Business Assets

- company total debt and liquidity indicators:

- net income and valuation multiples indicators:

RGNX - Annual Net Income|Projected Future Earnings REGENXBIO Inc.|RGNX - Market Cap to Earnings|Future Price to Earnings REGENXBIO|RGNX - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Regenxbio|RGNX - Operating profit before amortization|Net earnings per share (EPS TTM) REGENXBIO|RGNX - Earnings per share for the last twelve months|Quarterly EPS earnings growth regenxbio.com|RGNX - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year REGENXBIO Inc.

- sales and revenue indicators:

RGNX - Company Total Revenue|Company Future Sales Volume Regenxbio|RGNX - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Regenxbio|RGNX - Annual Revenue Growth (Last Twelve Months)

Fundamental company analysis:RGNX (Regenxbio)

REGENXBIO Inc. generates revenue through royalties from third-party drugs and promising proprietary developments with a limited pricing ceiling. These cash flows determine the market valuation of assets, directly impacting share prices. This metric measures the total business value by multiplying the number of issued shares by the current session closing price. It is critical for investors to monitor the risk of overvaluation during macrocycle shifts. By analyzing the company's full market capitalization, one can compare the issuer's scale against industry medians.

Key competitors